Drug Type Monoclonal antibody |
Synonyms Avaximab-TNF, AVX 470, AVX-1350 + [1] |
Target |
Mechanism TNF inhibitors(Tumor necrosis factor inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colitis, Ulcerative | Phase 1 | US | 01 Feb 2013 | |
Colitis, Ulcerative | Phase 1 | BE | 01 Feb 2013 | |
Colitis, Ulcerative | Phase 1 | CA | 01 Feb 2013 | |
Colitis, Ulcerative | Phase 1 | HU | 01 Feb 2013 | |
Neoplasms | Phase 1 | US | 01 Feb 2013 | |
Neoplasms | Phase 1 | BE | 01 Feb 2013 | |
Neoplasms | Phase 1 | CA | 01 Feb 2013 | |
Neoplasms | Phase 1 | HU | 01 Feb 2013 | |
Acute Radiation Syndrome | Preclinical | US | - |
Phase 1 | 33 | rscbjxukrw(lyrnoxoaao) = djneclzdrk vtstacmlqc (oejxgarfwk ) | - | 01 Jun 2016 | |||
Placebo | rscbjxukrw(lyrnoxoaao) = vdzrnfnbit vtstacmlqc (oejxgarfwk ) |